Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Neuroscience ; 329: 74-82, 2016 08 04.
Artigo em Inglês | MEDLINE | ID: mdl-27155149

RESUMO

SLC26A4 mutations cause fluctuating and progressive hearing loss associated with enlargement of the vestibular aqueduct (EVA). SLC26A4 encodes a transmembrane anion exchanger called pendrin expressed in nonsensory epithelial cells of the lateral wall of cochlea, vestibular organs and endolymphatic sac. We previously described a transgenic mouse model of EVA with doxycycline (dox)-inducible expression of Slc26a4 in which administration of dox from conception to embryonic day 17.5 (DE17.5) resulted in hearing fluctuation between 1 and 3months of age. In the present study, we hypothesized that Slc26a4 is required to stabilize hearing in DE17.5 ears between 1 and 3months of age. We tested our hypothesis by evaluating the effect of postnatal re-induction of Slc26a4 expression on hearing. Readministration of dox to DE17.5 mice at postnatal day 6 (P6), but not at 1month of age, resulted in reduced click-evoked auditory brainstem response (ABR) thresholds, less fluctuation of hearing and a higher surface density of pendrin expression in spindle-shaped cells of the stria vascularis. Pendrin expression in spindle-shaped cells was inversely correlated with ABR thresholds. These findings suggest that stabilization of hearing by readministration of dox at P6 is mediated by pendrin expression in spindle-shaped cells. We conclude that early re-induction of Slc26a4 expression can prevent fluctuation of hearing in our Slc26a4-insufficient mouse model. Restoration of SLC26A4 expression and function could reduce or prevent fluctuation of hearing in EVA patients.


Assuntos
Proteínas de Transporte de Ânions/administração & dosagem , Proteínas de Transporte de Ânions/deficiência , Terapia Genética , Perda Auditiva Neurossensorial/metabolismo , Perda Auditiva Neurossensorial/terapia , Aqueduto Vestibular/anormalidades , Animais , Proteínas de Transporte de Ânions/genética , Cóclea/crescimento & desenvolvimento , Cóclea/metabolismo , Cóclea/patologia , Modelos Animais de Doenças , Saco Endolinfático/crescimento & desenvolvimento , Saco Endolinfático/metabolismo , Saco Endolinfático/patologia , Potenciais Evocados Auditivos do Tronco Encefálico/fisiologia , Audição/fisiologia , Perda Auditiva Neurossensorial/patologia , Camundongos da Linhagem 129 , Camundongos Endogâmicos C57BL , Camundongos Transgênicos , Transportadores de Sulfato , Fatores de Tempo , Aqueduto Vestibular/metabolismo , Aqueduto Vestibular/patologia
2.
Yao Xue Xue Bao ; 46(4): 370-6, 2011 Apr.
Artigo em Chinês | MEDLINE | ID: mdl-21751488

RESUMO

The absorption of oral drug in the intestine is an important factor to determine the drug bioavailability. There are many intestinal transporters mediating drug absorption, distribution, excretion and drug-drug interaction. Understanding the transport mechanism can improve the effectiveness and safety of drug and guide clinical rational use of drugs. The in vivo and in vitro methods are used to predict the transport mechanism of drugs by intestinal transporters in the intestine. The purposes of this article are to introduce the main transporters in the intestinal tract, to explain the transport mechanism and to summarize the advantages and disadvantages of the research methods of them.


Assuntos
Transportadores de Cassetes de Ligação de ATP/metabolismo , Proteínas de Transporte de Ânions/metabolismo , Absorção Intestinal , Proteínas de Membrana Transportadoras/metabolismo , Simportadores/metabolismo , Transportadores de Cassetes de Ligação de ATP/administração & dosagem , Animais , Proteínas de Transporte de Ânions/administração & dosagem , Disponibilidade Biológica , Humanos , Proteínas de Membrana Transportadoras/administração & dosagem , Transportador 1 de Peptídeos , Simportadores/administração & dosagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...